You are here
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced upcoming presentations on the economic value of plazomicin and the costs associated with in-hospital treatment of bloodstream infections and sepsis at the ASHP Midyear 2018 Clinical Meeting in Anaheim, CA.
|Title:||Health economic value of plazomicin versus meropenem in the treatment of complicated urinary tract |
infections including acute pyelonephritis: cost-effectiveness analysis
|Poster:||4-111, Monday, December 3, 2018 from 2:30 - 4:00pm PST|
|Title:||Health economic value of plazomicin versus colistin in the treatment of carbapenem-resistant |
enterobacteriaceae bloodstream infections: a cost-effectiveness analysis
|Poster:||4-110, Monday, December 3, 2018 from 2:30 - 4:00pm PST|
|Title:||Economic burden of bloodstream infection among those who survive or die during the inpatient |
hospitalization: analysis of 2015 National Inpatient Sample
|Poster:||4-082, Monday, December 3, 2018 2:30 - 4:00pm PST|
The abstracts can be accessed through the ASHP Midyear 2018 website. Following the meeting, the posters will be available on the Achaogen website.
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization. For more information, visit the Achaogen website at www.achaogen.com.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential uses and advantages of ZEMDRI (plazomicin), Achaogen’s strategic and commercial objectives and the Achaogen pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of commercialization and gaining market acceptance, uncertainties inherent in the development process, the risks and uncertainties of the regulatory approval process and the risk when bacteria will evolve resistance to ZEMDRI. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on November 8, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether, as a result of any new information, future events, changed circumstances, or otherwise.
Investor and Media Contact:
Source: Achaogen, Inc.
© 2018 Achaogen, Inc. All Rights Reserved.